Search results
Results from the WOW.Com Content Network
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Its name is composed of the components olara-t-u-mab. This shows that the drug is a human monoclonal antibody acting against tumors. [34] The name of benralizumab, a drug designed for the treatment of asthma, has the components benra-li-zu-mab, marking it as a humanized antibody acting on the immune system. [42]
Biological response modifiers (BRMs) are substances that modify immune responses.They can be endogenous (produced naturally within the body) or exogenous (as pharmaceutical drugs), and they can either enhance an immune response or suppress it.
When treatment with DMARDs fails, cyclophosphamide or steroid pulse therapy is often used to stabilise uncontrolled autoimmune disease. Some severe autoimmune diseases are being treated with bone marrow transplants in clinical trials, usually after cyclophosphamide therapy has failed.
CTLA4 antibody that causes immune system-mediated lysis of the tagged cell: Unresectable or metastatic malignant melanoma. Life-threatening immune mediated reactions and fever. Nivolumab: IV: IgG4 antibody that functions as a checkpoint inhibitor, specifically inhibiting PD-1
The advantage of active monoclonal antibody therapy is the fact that the immune system will produce antibodies long-term, with only a short-term drug administration to induce this response. However, the immune response to certain antigens may be inadequate, especially in the elderly.
The most well-known compound in this class is fingolimod (FTY720), which was the first oral disease-modifying therapy approved for the treatment of relapsing-remitting MS. These drugs have the ability to modulate the G-protein coupled S1P receptors .